AIMT - Aimmune's Launch of Peanut Allergy Drug Will Take Time
Aimmune Therapeutics (NASDAQ: AIMT), a biopharmaceutical company that specializes in treatments for life-threatening food allergies, reported fourth-quarter results Thursday after the market close. Despite being down 14% at one point in Friday's trading, shares closed down only 2.5% on a day the market took a beating.
Investors weren't interested as much in the financials as they were to hear about the launch of Aimmune's peanut allergy drug, Palforzia, which was approved by the U.S. Food and Drug Administration (FDA) on Jan. 31. The company didn't take in any revenue in the quarter ended Dec. 31, as expected. The Palforzia launch is progressing, but complexities relating to the management of risk to patients means that revenue will ramp up slowly during the year.
Image source: Getty Images.